key: cord-0046788-7dr3pb10 authors: Lynch, Joseph P. title: INFLUENZA AND VIRAL RESPIRATORY INFECTIONS date: 2020-06-22 journal: Pharmacology and Therapeutics DOI: 10.1016/b978-1-4160-3291-5.50081-0 sha: 4d9bfee311c74c33c8a95c1dff014c5de366bc88 doc_id: 46788 cord_uid: 7dr3pb10 nan Infl uenza A and B viruses infect on average 10% to 15% of the population annually (all age groups are affected). 2, 3 Infl uenza causes seasonal outbreaks globally, and (rarely) pandemics. 4 Seasonal infl uenza epidemics from 1976 through 2001 were responsible for more than 200,000 annual hospitalizations and more than 30,000 infl uenza-associated deaths (IADs) (all causes) in the United States 5 (Fig. 77-1) . The toll is considerably higher during pandemics. 4 Infl uenza virus belongs to the virus family Orthomyxoviridae, which includes Infl uenzavirus A, B, and C. 6 Infl uenza A and B cause most human infections. 6 Most seasonal epidemics and all recognized pan-demics in humans are due to infl uenza A. Infl uenza A viruses are characterized by their antigenicity, according to hemagglutinin (H) and neuraminidase (N) proteins; there are 16 H and 9 N subtypes. 6 All antigen subtypes circulate among avian species. 6 Globally, the most common circulating infl uenza A viruses from 1994 to 2005 included H3N2 (90.6%), H1N1 (8%), and H1N2 (1.1%). 7 There is signifi cant variability among seasons, with H3N2-dominant years being worse than H1N1 years. 2, 8 Infl uenza viruses have evolved mechanisms that promote antigenic variability. Point mutations in the H gene give rise to new infl uenza strains of the same H type (termed antigenic drift; Fig. 77 -2). 3 In this context, existing antibodies may fail to cover the new variant. Antigenic drift mandates modifi cation of infl uenza vaccines annually. 3 A second mechanism, known as antigenic shift, is more dramatic and allows one infl uenza strain (such as H3N2) to acquire a completely new H or N gene (such as H1 or N1), resulting in a new virus (such as H3N1 or H1N2) (Fig. 77-3) . Pandemic infl uenza results when the antigenic mutations are dramatically different from previously circulating strains; this could occur by antigenic shift or by cross-species transmission of novel H-or Ntype viruses. 3 The recent emergence of the highly pathogenic avian viruses (H5N1) 4 is discussed later. Infl uenza is one of the most common and important respiratory illnesses, affecting all ages. In temperate climates, infl uenza exhibits a seasonal pattern, with peak activity during the winter months (December through March). 2 Local outbreaks abate after 6 to 8 weeks. 2 Infl uenza A predominates in most seasons, but epidemics of infl uenza B occur. 9 The virus is present in high titer in respiratory secretions and is transmitted as a small-particle aerosol generated by coughing and sneezing. 2 Person-to-person spread by direct contact with respiratory secretions may also occur. Children are important as vectors for transmission to adult populations. 10 Spread throughout the general population often includes nosocomial outbreaks in nursing homes and other closed communities. 1 The severity of infl uenza epidemics varies among seasons, depending upon the virulence and antigenicity of the predominant circulating strain and immune status of the population at risk. The 1984-1985 infl uenza season was severe, with an estimated 51,000 IADs in the United States compared to fewer than 8000 IADs during the 1978-1979 season. 8 Approximately 90% of deaths occur among the elderly, in contrast to approximately 150 annual deaths in the United States in children under age 5 years. 8 Infl uenza and serious complications of infl uenza are more common in the elderly (age >65 years), children under age 2 years, adults or children with concurrent illness (e.g., pulmonary, cardiac, metabolic), residents of chronic care facilities, and pregnant women. 2, 11 Pandemics occur infrequently but can be devastating. 12 The most recent global pandemics included 1918-1919 (Spanish fl u, H1N1; responsible for up to 50 to 100 million deaths worldwide); 1957-1958 (Asian fl u, H2N2; >1 million deaths); and 1968-1970 (Hong Kong fl u, H3N2; >700,000 deaths). 4 Given the considerable growth of the population worldwide and exponential growth in foreign travel over the past 50 years, another pandemic could be catastrophic ( Fig. 77-4) . Following an incubation period of 2 to 5 days, symptom onset is generally abrupt, distinguishing infl uenza from other viral respiratory infections. Fever is present in more than 90% of cases; other symptoms include a dry, nonproductive cough, nasal congestion or rhinorrhea, headache, sore throat, and constitutional complaints (e.g., myalgias, malaise, fatigue, prostration). 10, 13 Infl uenza is an important cause of respiratory illness in children. 10 Most infl uenza infections in children are self-limited, but infl uenza may be severe in young children (age <2 years) or those with chronic medical conditions. 2 Infl uenza is associated with increased hospitalizations, 14 outpatient visits, 15 and health care costs 15 in children. In previously healthy individuals (children or adults), symptoms resolve spontaneously within 5 to 8 days. The course may be protracted, and complications more frequent, in high-risk or immunocompromised patients. 2, 16, 17 Primary infl uenza pneumonia, characterized by diffuse interstitial infi ltrates and severe hypoxemia, is unusual except during pandemics or in individuals with specifi c risk factors. 2 Secondary bacterial pneumonia may complicate infl uenza, usually 7 to 21 days following resolution of the initial illness. 2 Acute respiratory distress syndrome may occur with some infl uenza strains, likely mediated by a virus-induced cytokine storm. 18 Serious nonrespiratory complications of infl uenza are rare, but include encephalopathy, pericarditis, rhabdomyolysis, and renal failure. 2, 19 Central nervous system complications are more common in children than adults. 19 Reye's syndrome, a severe neurologic complication of infl uenza in children, has largely disappeared since the link between aspirin use and Reye's syndrome was discovered. 20 Clinical features of infl uenza are nonspecifi c. 21 Laboratory confi rmation of infl uenza is necessary if infection control measures and treatment are to be optimized. Culture of respiratory secretions is the gold standard, but can take 3 to 5 days and is expensive and often not available in an outpatient setting. Virus titers are high early in the illness, but fall rapidly in adults. In one study, only 48% of hospitalized elderly persons with confi rmed infl uenza had a positive culture. 21 Commercialized kits allow rapid detection of infl uenza antigens in less than 1 hour with a sensitivity of 40% to 80%. 6, 21 Reverse transcriptasepolymerase chain reaction (RT-PCR) is more sensitive than viral cultures or antigen detection tests, but is less readily available. 10 Rapid diagnostic tests may be invaluable during epidemics in emergency departments and outpatient and inpatient settings. Currently, four drugs are licensed in the United States for the treatment or prophylaxis of infl uenza. 22 These include the adamantanes (i.e., amantadine and rimantadine) and the neuraminidase inhibitors (NAIs) (e.g., oseltamivir and zanamivir). 23 Currently, NAIs are the therapeutic agents of choice for treatment or prevention of infl uenza infections. Treatment should be considered for patients with infl uenzalike illness (ILI) in communities where infl uenza has been documented, especially those with underlying high-risk conditions. 22 Further, patients hospitalized with acute respiratory illness during an epidemic period may be candidates for treatment. Prophylaxis with NAIs is appropriate during infl uenza seasons for household contacts or asymptomatic high-risk patients such as nursing home residents or staff during an outbreak, or for unvaccinated persons at high risk (e.g., with chronic lung disease, immunosuppressed, etc.). 23, 24 The adamantanes block the infl uenza A virus M2 ion channel protein, thereby preventing replication within infected cells; these agents have no activity against infl uenza B 2,22 . In early studies, both amantadine (Symmetrel; licensed in 1966) and rimantadine (Flumadine; licensed in 1993) were shown to be effective to treat 22, 25 or prevent 22 uncomplicated infections due to sensitive infl uenza A. Amantadine or rimantadine are equally effective, provided that the drug is administered within 48 hours of onset of symptoms. 22, 25 Importantly, resistance to adamantanes may emerge rapidly. 7, 26, 27 Resistance to adamantanes is due to single amino acid substitutions within the viral M2 protein 7 that confer cross-resistance to both agents. 22, 26 Although resistance to adamantanes among untreated individuals has remained low (<1%) through the 1990s, 7 resistance rates to infl uenza A viruses (H3N2, H1N1, or H1N2) have skyrocketed within the past few years. 7, 26 The increase in resistance was weighted heavily by isolates from Asia. 7,28 By 2004 7,28 By -2005 , rates of adamantane resistance in selected Asian locales included 96% (China), 72% (Hong Kong), 42% (Singapore), and 36% (South Korea). 27 Resistance to adamantanes has also escalated dramatically in North America. 7 By the 2005-2006 infl uenza season in the United States, greater than 90% of isolates of infl uenza A (H3N2) from the United States or Canada submitted to the Centers for Disease Control and Prevention (CDC) were resistant to adamantanes. 27 In view of these extraordinarily high rates of resistance, adamantanes should not be used for the treatment or prophylaxis of infl uenza A in the United States. 29 Currently, adamantanes have little role to treat or prevent infl uenza. NAIs are analogues of N-acetylneuraminic acid (the cell surface receptor for infl uenza viruses) and inhibit the enzyme neuraminidase, reducing viral replication 22, 23 (Fig. 77-6 ). Inhibition of neuraminidase reduces viral replication. 22 NAIs are active against both infl uenza A and B, but activity against infl uenza B is less. 9, 23 Currently available NAIs include oseltamivir and zanamivir. Oseltamivir. Oral oseltamivir (Tamifl u) is approved to treat infections due to infl uenza A or B and for prophylaxis of infl uenza among persons greater than 1 year old. Oseltamivir is not approved for infants less than 1 year of age since studies are lacking in this age group. 23 For treating acute infl uenza, the dose in adults or children greater than 12 years old is 75 mg twice daily for 5 days; the dose is lower in children 1 to 12 years old (adjusted for weight). 22, 30 For prophylaxis, the dose is 75 mg daily for 10 days. 22 Early treatment with oral oseltamivir in patients with acute infl uenza (A or B) shortens the course and reduces complications in previously healthy children or adults and high-risk patients. 9, 25, 31 NAIs are effi cacious only if administered within 48 hours of onset of symptoms. 23, 25 Duration of symptoms is shortened by 1 to 2 days in patients receiving NAIs (compared to placebo). 23 Large studies in North America found that patients with ILI treated with oseltamivir during the infl uenza seasons from 1999 to 2004 had lower rates of pneumonia, hospitalizations, or deaths (within 30 days) compared to untreated patients. 31, 32 In controlled, randomized trials, administration of oseltamivir as prophylaxis reduced the risk of infl uenza in unvaccinated healthy adults, household contacts, nursing home residents, and the elderly. 30, 33 Oseltamivir prophylaxis was effi cacious in a cohort of 45 hematopoietic stem cell transplant recipients at high risk. 24 The use of oseltamivir during infl uenza outbreaks in nursing homes was associated with reductions in hospitalizations, deaths, and antibiotic use compared to patients receiving either amantadine or no therapy. 34 Zanamivir. Zanamivir (Relenza) is approved to treat infections due to infl uenza A or B and for prophylaxis of infl uenza in children greater than 5 years of age. 22, 23 Zanamivir is administered by a dry powder inhaler (Diskhaler) delivered directly to the respiratory tract. 23 For treating acute infl uenza, the dose is 10 mg twice daily for 5 days (children or adults). 22 For prophylaxis (e.g., contacts of index cases), the dose is 10 mg once daily for 10 days. 22 Zanamivir achieves high concentrations in the respiratory tract (1000 times the 50% inhibitory concentration for neuraminidase). 23 The inhibitory effect starts within 10 seconds. 23 These properties reduce the chance for emergence of resistant viruses. The major drawback to zanamivir is the inability of young children or adults with neurologic or muscular defi cits to use the Diskhaler. Zanamivir (10 mg twice daily for 5 days) is effective therapy for infl uenza A or B in adults and children (age >5 years) and has minimal toxicity. 22 The duration of symptoms was shorted by 1 to 2.5 days, and complications were reduced, provided zanamivir was initiated within 30 hours of the onset of symptoms. 22 Inhaled zanamivir (10 mg once daily for 10 days) was effective (55% to 80%) as chemoprophylaxis of infl uenza in healthy adults and healthy household contacts (children >5 years old or adults). 2, 35 Adverse Effects with NAIs. Adverse effects with NAIs are uncommon. 22, 23, 29 Resistance to NAIs is rare 36-38 but can arise by single amino acid substitutions at N or H residues. 39 Mutations at N residues are more clinically relevant. 39 Mutations in N that prevent oseltamivir from binding to the N active do not affect zanamivir. 37 Resistance to oseltamivir was noted in 4% to 8% of children and less than 1% of adults after treatment with oseltamivir. 2, 40 Higher rates of oseltamivirresistant mutants were detected in Japan (18%) in children treated with oseltamivir (possibly refl ecting subtherapeutic doses). 41 The recent epidemic of avian infl uenza A (H5N1) infection in Asia 42 raises the possibility that NAI-resistant mutants could emerge as a result of increasing exposure to oseltamivir. 43 Importantly, most oseltamivirresistant isolates remain susceptible to zanamivir. 37 Vaccines are the cornerstone for control of infl uenza. 22, 44, 45 Infl uenza vaccines are developed annually, with input from the World Health Organization (WHO) and national authorities. 46 Viruses must be reformulated annually, since genetic mutations arise continuously in infl uenza viruses in a process termed antigenic drift. 46 Given the potential for pandemic infl uenza (e.g., with the antigen shift or the avian H5N1 strain) ( Fig. 77-7) , 12 the WHO has developed an action plan to increase vaccine supply. 46 However, current technologies for developing vaccines (i.e., egg-based manufacturing process) are slow, and existing supplies of vaccines would be inadequate in the face of a global pandemic. 12 Currently available infl uenza vaccines include the trivalent inactivated vaccines (TIVs) and live, attenuated infl uenza vaccine (LAIV). 47 Both vaccines contain the predicted antigenic variants of infl uenza A (H3N2, H1N1) and infl uenza B viruses. 3 The inactivated vaccine is administered intramuscularly; LAIV is given as an intranasal spray (FluMist; MedImmune). 3 TIV evokes a higher systemic response (i.e., serum immunoglobulin G antibody response) whereas LAIV elicits a better immunoglobulin A mucosal response at the site where viruses enter the body. 3 In the United States, TIV is approved for individuals greater than 6 months of age; LAIV is approved for healthy persons 5 to 49 years of age. 48 No vaccines are approved for infants under the age of 6 months. Provided the strains encompassed by the vaccine match the circulating epidemic strain, inactivated vaccines provided 70% to 100% protection among healthy adults and 30% to 60% protection among the elderly or young children. 22, 47 Serum antibody responses to infl uenza vaccination may be blunted in the elderly, immunocompromised individuals, and preschool children. 22 In adults, LAIV may be less effective than TIV, which may refl ect reduced activity against infl uenza B viruses. 47 Infl uenza vaccination is benefi cial in adults greater than 65 years old living in the community 45, 49 or nursing homes. 13 Benefi ts of vaccination include lower mortality (all causes), hospitalizations, and pneumonias. 2, 45, 49 Further, infl uenza vaccination reduced mortality, hospitalizations, and outpatient visits for patients less than 65 years of age with concurrent medical conditions. 50 Additionally, vaccination of health care workers is highly effective in protecting high-risk patients. 44, 51, 52 Infl uenza vaccination (either TIV or LAIV) in healthy children reduces the incidence of laboratory-confi rmed cases of infl uenza and acute otitis media (AOM). [53] [54] [55] Vaccination of children in day care centers or schools reduced the incidence of ILI among family contacts or in the community at large. 2, 55 Indirect benefi ts of vaccinating children include fewer parental days lost from work and less impaired work productivity. 3 Recommendations for annual infl uenza vaccination are published annually by the CDC. In 2007, the CDC recommended annual infl uenza vaccination for the following populations: children or adults at high risk for complications of infl uenza, close contacts of high-risk persons, all children ages 6 to 59 months, and all adults greater than 50 years old (regardless of health status) 29 (Box 77-1). Indications for vaccination continue to evolve. Many experts favor expanding infl uenza vaccination, potentially toward universal vaccination. 44 Adverse effects from infl uenza vaccination are minimal. 22 With the inactivated vaccine, mild soreness of the arm at the site of vaccination may persist for 1 to 2 days. 22 Serious adverse effects are rare. The vaccine is contraindicated in patients who are allergic to eggs, but even in this context serious hypersensitivity reactions to the vaccine are rare. LAIV is well tolerated 3,47,56 but should not be administered to immunocompromised individuals. Avian infl uenza is a highly virulent H5N1 subtype of infl uenza. 4 The ongoing global epidemic of epizootic avian infl uenza infection has been responsible for the death or destruction of greater than 140 million birds. 4 Infections due to avian infl uenza viruses are rare in humans, but the antigenic novelty of H5N1 suggests the potential for pandemic spread. 4 Infections in humans due to H7 and H9 avian infl uenza viruses are typically mild. By contrast, the H5N1 avian virus causes serious respi- ratory infections, with case fatality rates of greater than 50%. 4 Sequence analysis suggests that the current H5N1 virus originated by reassortment between multiple co-circulating avian infl uenza strains prevalent in Hong Kong in 1997. 57 Certain unique structural features in the H5N1 virus are present among highly pathogenic viruses infecting chickens but are not common among the avian viruses circulating among wild birds. 4 This suggests that transmission to humans originated from poultry rather than wild birds. The avian viruses exhibit preferential binding to sialic acid α2-3 linkages, which are sparse in the human upper respiratory tract. 58 This may explain the absence of human-to-human transmission. Outbreaks of severe infl uenza in humans with highly virulent H5N1 strains derived from infected poultry were reported in China and Southeast Asia in 2003. 59 The fi rst known transmission of H5N1 viruses from birds to humans took place in 1997, shortly following an outbreak of sick geese on a farm in Guangdong Province of China. 60 A fatal infection in May 1997 in Hong Kong was followed by 17 cases (5 died) in November-December 1997. 4 The outbreak ceased after Hong Kong culled 1.5 million poultry in 3 days and banned the import of poultry from mainland China. 57 No further human cases were recognized until February 2003, when at least two confi rmed cases were identifi ed in Hong Kong. 61 Subsequent cases in China, Vietnam, Thailand, Cambodia, and other Southeast Asian countries were followed by human cases in Europe, Russia, the Middle East, and Africa 4,59 ( Fig. 77-8) . The virus has spread along the fl yways of migratory birds to more than 30 countries worldwide. 4 By August 2006, 238 cases had been cited in humans, with 139 deaths (58%). 4, 59 Large-scale culling operations and intensifi ed surveillance led to eradication of H5N1 infection in poultry in some countries. However, in many countries, H5N1 infection is endemic in wild birds and poultry. 4 In countries where human contact with poultry is common, the likelihood of further adaptation of the virus to humans and transmission between humans is high. H7 and H9 avian infl uenza viruses are highly lethal in poultry, but typically cause mild symptoms in humans (e.g., conjunctivitis with subtype H7 62, 63 or mild ILI with H9N2). 59, 64 In sharp contrast, human cases of H5N1 have been characterized by severe pneumonia with high fatality rates (58%). 59 Ninety percent of cases occurred in individuals less than 40 years old. 59 Most cases had close contact with poultry in the week preceding the illness. 42 Human-to-human transmission has been rare. 65 The most common symptoms among documented cases of H5N1 include fever (98%), cough (88%), dyspnea (62%), rhinorrhea (55%), sore throat (52%), diarrhea (39%), myalgias (29%), headache (28%), and abdominal pain (23%). 42 Diarrhea may precede the onset of respiratory symptoms. Pulmonary infi ltrates on chest radiographs were noted in 88% of cases 42 ; this likely overestimates the true incidence since asymptomatic or mild cases may have been missed. Elevated liver enzymes, lymphopenia, and thrombocytopenia were noted in 50% to 67% of cases. 4, 42 Pathology revealed diffuse alveolar damage, reactive hemophagocytosis in the bone marrow, and lymphoid depletion in the spleen and lymph nodes. 4 Cultures of pharyngeal or nasal swabs or respiratory secretions may confi rm the diagnosis, 42 but should be performed only in laboratories meeting biosafety level III or higher requirements. 4 Rapid antigen tests are insensitive. 4 RT-PCR methods are more sensitive and specifi c, and do not require handling of live virus. 4 Because of the high risk of nosocomial spread, patients with suspected H5N1 should be isolated and placed in negative pressure rooms (if available). 4 Strict infection control measures among health care workers and all contacts are mandatory. Antiviral treatment should be initiated as early as possible, and should be continued if active viral replication continues. 42 Controlled trials evaluating adamantanes to treat H5N1 infections in humans are lacking. However, resistance to adamantanes is considerable in some regions. Point mutations in the M2 region (conferring resistant to adamantanes) were detected in greater than 95% of H5N1 isolates from Vietnam and Thailand but fewer than 10% of isolates from Indonesia and China. 66 Because of the potential for rapid emergence of resistance, adamantanes should not be used irrespective of in vitro susceptibility. 4 NAIs display in vitro activity against H5N1, but controlled trials assessing these agents in humans are lacking. Currently, the WHO recommends oseltamivir as the fi rst-line drug to treat suspected H5N1 infections. 4 Because humans lack immunity against H5N1, a higher dose (150 mg twice daily) and longer duration (7 to 10 days) should be considered. 4 Resistance to oseltamivir has been detected in some treated patients. 4 Some oseltamivir-resistant isolates displaying the H274Y mutation remain susceptible to zanamivir. 37 Chemoprophylaxis with oseltamivir or zanamivir should be considered for patients at high risk for transmission (e.g., household or close contact, exposure to infected poultry or environmental source, health care workers or laboratory personnel without appropriate protec- Annual vaccination against infl uenza is recommended for • All persons, including school-aged children, who want to reduce the risk of becoming ill with infl uenza or of transmitting infl uenza to others; • All children aged 6-59 months (i.e., 6 months-4 years); • All persons aged 50 years and older; • Children and adolescents (aged 6 months-18 years) receiving long-term aspirin therapy who therefore might be at risk for experiencing Reye's syndrome after infl uenza virus infection; • Women who will be pregnant during the infl uenza season; • Adults and children who have chronic pulmonary ( Respiratory syncytial virus (RSV) is a common respiratory virus affecting persons of all ages. 68, 69 The spectrum of RSV disease ranges from a mild "cold" to severe respiratory failure. 68, 69 RSV is the leading cause of lower respiratory tract infection in young children but is also an important pathogen in adults, 70 particularly in the elderly 71 or patients with comorbidities. 68, 70, 72 Virology RSV is an enveloped RNA virus within the family Paramyxoviridae and the genus Pneumovirus. 68 Human RSV isolates are classifi ed into two major groups (A and B) based primarily upon antigenic differences in the G protein. 68 Both A and B strains circulate concurrently, with A strains usually predominating. 69 Several distinct genotypes exist; annual changes in the dominant strains may evade immune defenses, leading to frequent reinfections 69 ( Fig. 77-9 ). RSV is the chief cause of hospitalization for respiratory tract infections (RTIs) in children, 69 and is second to infl uenza as a cause of serious viral RTIs in adults. 68, 71, 73, 74 Primary RSV infection is nearly universal by age 2; due to incomplete immunity, reinfections are common throughout life. 68, 69 In adults, RSV infections are more common in those with comorbidities (e.g., pulmonary or cardiac disorders), impaired immunity, or advanced age. 68, 71 However, RSV may infect previously healthy adults. 75 Epidemiologic studies implicated RSV in 3% to 5% of cases of community-acquired pneumonia in adults and in 6% to 22% of acute exacerbations of chronic obstructive pulmonary disease (COPD). 68, 73 Outbreaks of RSV infections have been described in closed populations (e.g., nursing homes, senior day care centers, health care workers, 68 and military recruits in training 75 ). The spectrum of RSV (in both children and adults) ranges from a trivial cold to severe (sometimes fatal) respiratory failure. 68 In infants, RSV typically presents as bronchiolitis, with low-grade fever, rhinorrhea, cough, wheezing, and poor feeding. 68, 69 Physical examination reveals crackles and expiratory wheezing. In severe cases, intercostal retraction, hypoxemia, and respiratory failure may ensue. The disease usually resolves spontaneously, but cough or bronchial hyperreactivity may persist for days or even weeks. In young adults, RSV typically gives rise to mild upper respiratory tract (URT) symptoms (e.g., nasal congestion, rhinorrhea, sore throat) that resolve over 4 to 10 days. 68 However, cough, wheezing, dyspnea, and a protracted course may occur. 68, 69 Symptoms of RSV and infl uenza overlap, but nasal symptoms, cough, wheezing, and sputum are more common with RSV, whereas myalgias are more common with infl uenza. 76 Even in previously healthy adults, RSV may cause missed work days and incurs economic costs. 68, 69 Severe RSV pneumonia is uncommon, but can occur in elderly patients or those with comorbidities 71, 76 or (rarely) in previously normal adults. 68, 70 Chest radiographs in RSV pneumonia are variable, and range from faint interstitial opacities (mimicking heart failure) to lobar consolidation. 68, 76 Concomitant infection with bacterial pathogens has been noted in 15% to 30% of patients with RSV pneumonia. 68,76 RSV may be a cause of exacerbations of asthma 68, 71 or COPD 77,78 in adults (par-ticularly during the winter months) and was linked to a more rapid decline in lung function in a cohort of COPD patients. 79 Laboratory diagnosis of RSV can be established via four methods: viral culture, antigen detection by immunofl uorescence assay (IFA) or enzyme immune assay (EIA), RNA detection by RT-PCR, and serologies. 68 Sensitivity of cultures or antigen detection ranges from 9% to 45%; sensitivity of RT-PCR is higher (60% to 90%). 68 RT-PCR is sensitive (>70%) and specifi c (99%), 68 and is the preferred method to detect RSV. RT-PCR may be obtained from nasal swabs, nasal washes, sputum, or bronchoalveolar lavage fl uid (BALF). 68 In adults, sputum or BALF are more sensitive than nasal specimens. 68 Unfortunately, RT-PCR is complex, expensive, and not available in many hospitals. Serologies are useful in epidemiologic surveys, but are of limited practical value in individual patients. 68 Given the limitations of diagnostic methods, and limited therapeutic options (discussed later), an aggressive diagnostic evaluation for RSV is rarely performed in clinical practice. However, nasal or BALF cultures and antigen detection assays should be considered for patients with severe disease or immunocompromised status. 68 RT-PCR is reserved for research or commercial laboratories in selected high-risk patients. Treatment is supportive. Bronchodilators may be useful in patients with wheezing or a history of asthma or COPD. 71 Aerosolized ribavirin is approved for RSV infections in infants, but not all studies cited benefi t. 68 Ribavirin is diffi cult to administer, requiring continuous inhalation by face mask or tent for 18 hr/day. 68 Alternatively, high-dose ribavirin (i.e., 2 g aerosolized for 2 hr three times daily) may be considered. 80 One multicenter trial randomized 14 hematopoietic stem cell transplant (HSCT) recipients with RSV URT infections to aerosolized ribavirin (2 gm t.i.d.) or standard care. 80 Progression to pneumonia was noted in one of nine patients receiving ribavirin compared to two of fi ve patients receiving supportive care (P = 0.51). At 10 days, viral loads were lower in ribavirin recipients (P = 0.07). These data are insuffi cient to judge effi cacy. Currently the role of ribavirin (either aerosolized or intravenous) in adults remains controversial. In a nonrandomized trial, RSV-IVIG (a human polyclonal immunoglobulin with high neutralizing antibody titers), combined with inhaled ribavirin, decreased viral shedding and was associated with lower mortality in HSCT recipients with RSV pneumonia. 81 Palivizumab (Synagis) (a humanized monoclonal antibody directed against the fusion protein of RSV) is approved for prophylaxis against RSV (once monthly for 5 months during winter season) in high-risk infants. 68 However, in a randomized trial of 43 immunocompetent children with RSV infection, palivizumab (n = 22) was no better than placebo (n = 21). 82 Further, a retrospective study of 40 allogeneic HSCT recipients (mostly adolescents) with symptomatic RSV infection found that palivizumab (administered to 19 patients) had no effect on survival or clinical end points. 83 No RSV vaccine is currently available, but several candidate vaccines are under development. 67, 68 Data regarding passive immunization with intravenous immune globulin (IVIG) or palivizumab in adults are lacking. Since RSV is transmitted by fomites and large droplets, infection control (particularly handwashing) is important to limit the spread of nosocomial RSV. 68 Masks are not required because RSV is not transmitted via aerosol. 68 Parainfl uenza viruses (PIVs) cause a spectrum of respiratory illnesses similar to those caused by RSV, but are usually milder. 69 Infection is limited to the URT in 40% to 60% of cases, and croup (laryngotra- cheobronchitis) is a cardinal symptom, noted in 10% to 44%; lower respiratory tract infections (LRTI) are infrequent (<10%) in immunocompetent patients. 69, 84 PIV typically infects children less than 3 years of age, but reinfections may occur in adults, particularly the elderly or those with pulmonary disease 77, 78 or immunosuppression. 16, 69 Virology PIV types 1, 2, 3, and 4 are enveloped RNA virus within the family Paramyxoviridae 69 (see Fig. 77-9 ). Most children are infected with PIV within the fi rst 2 years of life. While URT symptoms predominate, parainfl uenza is second only to RSV (and possibly human metapneumovirus [hMPV]) as a cause of viral bronchiolitis and pneumonia in children. 67, 69 Most children are infected with PIV type 3 by age 2 years and by types 1 and 2 by age 5 years. 69 PIV type 4 is rare. 16, 69 Pneumonia or bronchitis from type 3 PIV occurs primarily in infants less than 6 months old. 69 PIV infections exhibit distinct seasonal patterns. 69 Type 1 PIV causes the largest outbreaks, with sharp rises in autumn of odd-numbered years. 69 PIV type 2 infections are less predictable but usually follow type 1 outbreaks. Type 3 PIV infections occur annually, usually in the spring and summer. A seasonal pattern has not been noted for PIV type 4. PIV replicates in the nasopharyngeal epithelium and spreads to the lower respiratory tract 1 to 3 days later. 69 Transmission occurs by close or direct contact with large droplets or fomites. 69 The duration of viral shedding in healthy people is approximately 1 week, but PIV shedding for greater than 4 weeks has been noted in immunocompromised patients. 16, 85 Infections with PIV are less common than RSV in children and adults, and are typically milder. PIV can infect COPD patients during peak seasons 77, 78 and can infect the elderly or healthy adults. In a cohort of senior day care attendees, PIV was implicated in 2.7% of acute respiratory infections; RSV accounted for 21%. 86 In a study of respiratory infections in 256 military recruits, PIV was isolated by culture in 3%; adenovirus (AdV) was detected in 48% and infl uenza in 11%. 75 PIV infections were cited in 2% to 7% of adult and pediatric HSCT recipients. 16, 85, 87, 88 Data on solid organ transplant (SOT) recipients are limited. PIVs cause a spectrum of respiratory illnesses similar to those caused by RSV, but are milder. 69 Most are upper respiratory tract infections (URTIs); 30% to 50% are complicated by AOM. 69 Croup is the cardinal symptom of PIV infections (noted in 10% to 44%), and is the main cause of hospitalization from PIV infections in children 2 to 6 years of age. 69 The lower respiratory tract is involved in only 15% of cases; 2.8 of 1000 children with such infections require hospitalization. 69 Similar to RSV, PIV may precipitate exacerbations of asthma in children and adults. 69 Reinfections may occur in adults, particularly the elderly. 69 PIV may cause bronchitis or pneumonia in organ transplant recipients 87 and human immunodefi ciency virus-infected or immunocompromised 16 patients. However, even among HSCT recipients, PIV infections are often confi ned to the URT. In a series of 198 HSCT patients with PIV-3 infection, 87% presented with URTI symptoms only; 6% had simultaneous URTI and LRTI symptoms. 88 The disease progressed from URTI to LRTI in 25 patients (13%). Progression was more likely among patients receiving corticosteroids. 88 PIV is a risk factor for airfl ow decline in HSCT recipients and a cause of long-term pulmonary complications. 89 As with other viruses, laboratory diagnosis of PIV can be established by viral culture, antigen detection (by IFA or EIA), RT-PCR, or serologies. 69 Given the low prevalence of PIV in adults, and the lack of effective therapy, diagnostic assays are rarely performed in clinical practice. No licensed or proven therapy for PIV is available. Ribavirin has in vitro activity against PIV, and aerosolized or intravenous ribavirin has been used to treat or prevent PIV infections in immunocompromised hosts, 87, 88, 90 but effi cacy remains uncertain. 16, 69 Prevention Currently there is no vaccine for PIV, 16 but several vaccines are being developed. 67 hMPV, a paramyxovirus discovered in 2001 in the Netherlands, 91 causes upper and lower RTIs in all age groups, but predominantly affects young children 92, 93 and immunocompromised or frail, elderly patients. 94 The spectrum of hMPV is similar to RSV, ranging from mild URTIs to severe bronchiolitis and pneumonia. 91, 92, 95, 96 Virology hMPV is a member of the Paramyxoviridae family, Pneumovirinae subfamily, and Metapneumovirus genus 94 (Fig. 77-10) . Two major genotypes (A and B) and four subgroups (A1, A2, B1, and B2) are recognized. 93, 97 One research group suggested that genotype A may be more virulent than genotype B, 97 but others found no difference between genotypes. 93 The predominant genotype (A or B) may vary between seasons. 93, 94 Epidemiology hMPV has a global distribution. 93, 94, 98 It was fi rst identifi ed in 2001, 91 but has been circulating (based on serologic studies) for 50 years in the Netherlands 98 and at least 15 to 20 years in North America. 99 hMPV accounts for 5% to 12% of acute RTIs in children (next to RSV and infl uenza). 93, 97, 98, 100 Serologic studies suggest that virtually all children are infected by the age of 5 to 10 years. 91, 94 More than three quarters of hMPV infections are in children less than 2 years old, 101 but all ages may be affected. 95, 98 Infections due to hMPV (both children and adults) are more common in immunosuppressed individuals. [102] [103] [104] In adults, hMPV accounts for 2% to 7% of acute RTIs 101, 105 or ILIs and may be implicated in 5% to 10% of acute exacerbations of asthma, 92 COPD, 106 or congestive heart failure. 106 Transmission of hMPV is similar to RSV (i.e., via respiratory droplets and hand-to-mouth or hand-to-eye contact with contaminated surfaces). 94 Outbreaks of hMPV respiratory infections have been described in long-term care facilities 95, 107 and health care workers (i.e., case contacts). 107 Like other respiratory viruses, hMPV predominates in winter and spring in temperate climates. 97, 98, 101 However, outbreaks may occur in the late spring 93 or summer. 107 Clinical symptoms of hMPV infections in infants and young children are indistinguishable from RSV. 92, 97, 98, 100, 101, 108 In previously healthy children, the most common features of hMPV were bronchiolitis (59%), croup (18%), exacerbation of asthma (14%), and pneumonia (8%). 101 Vomiting was less common in hMPV infections (10%) compared to RSV (31%) or infl uenza (28%). 101 Hospitalization is rarely required in previously healthy children, 101 but severe pneumonia can occur in children with comorbidities or immunosuppression. 97, 98 Co-infection with RSV and hMPV occurs in 4% to 6% of cases. 101, 109 Like other respiratory viruses, hMPV may evoke exacerbations of asthma in children. 94 In young children, AOM occurs in one third to one half of cases. 92, 94, 101 Conjunctivitis was noted in 4% of children with hMPV versus 22% of children with infl uenza infections. 101 In adults, hMPV may cause exacerbations of asthma 92 or COPD. 110 Infections due to hMPV are usually self-limited (in children and adults), 94,101 but fatal pneumonia may occur. 94, 95 Among fatal cases, diffuse alveolar hyaline membrane damage and peribronchiolitis have been observed. 94, 95 Because of the presence of multiple viral genotypes and waning immunity, 95 reinfections may occur throughout life. 94 Reinfections are typically milder than primary infections. 94 Diagnosis hMPV exhibits fastidious growth requirements in culture and may require 14 to 21 days to grow. 93, 94 A rapid antigen test is not available. RT-PCR is the preferred means to diagnose hMPV. 93, 95, 98 No sensitive anti-hMPV antibody tests are currently available. 93 No antiviral or antibody preparation is approved for the treatment of hMPV. Intravenous ribavirin has shown promise in vitro and in animal models. 111, 112 Inhaled ribavirin was ineffective in one HSCT recipient 104 ; however, in a lung transplant recipient, intravenous ribavirin was associated with a favorable response. 103 Intravenous polyclonal antibodies inhibit hMPV, and have a plausible (albeit untested) role in treating serious cases. 112 Live, attenuated vaccines have shown effi cacy in animals, but vaccines are not yet available in humans. 67 Rhinovirus and coronavirus infections account for more than 50% of common colds. 113, 114 Symptoms include rhinitis, pharyngitis, sneezing, hoarseness, sinusitis, and cough; bronchopneumonia is rare. 113, 115 These viral infections usually are self-limited, 113 but complications may arise in immunosuppressed individuals 16, 116 or patients with cardiac or pulmonary disease. 113, 117 Virology Both are single-stranded RNA viruses (Fig. 77-11) . Rhinoviruses are members of the Picornaviridae family; more than 100 serotypes exist. 113 Variations in surface proteins account for antigenic diversity. 113 Coro-naviruses are divided into three genera and can infect humans, animals, and birds. 113 Both rhinoviruses and coronaviruses cause respiratory infections (predominantly URTIs) in all age groups. 113, 115 In temperate climates, rhinoviral illnesses peak in the early fall and spring 115 ; coronaviruses peak in the late fall, winter, and early spring. 113 Schools, day care centers, family members, and businesses are sources of transmission. 113 Rhinoviruses account for approximately 50% of common colds; coronaviruses, 15%. 113, 114 Rhinoviruses or coronaviruses may also cause exacerbations of asthma 115 or COPD. 117 In children, these viruses may serve as cofactors for AOM. 118,119 These viral infections usually are selflimited, 113, 115 but complications (including fatal pneumonias) may arise in immunosuppressed individuals. 16, 116 Diagnosis Conventional virus culture methods are sensitive for rhinoviruses, but insensitive for coronaviruses. 113, 120 RT-PCR is more sensitive than cultures for rhinovirus and coronavirus. 120 Serologies are not helpful in clinical practice and are not available in most centers. 113 Given the mild and self-limited course observed with these viruses, cultures or RT-PCT are rarely performed, except in epidemiologic or research studies. No proven therapy for rhinoviruses or coronaviruses is available. Vaccines are not available. 113 Severe acute respiratory syndrome (SARS) emerged in the Guangdong Province of southern China in 2002 121 and was followed by a pandemic. In less than one year, more than 8000 cases were identifi ed in 26 countries, with a case fatality rate of 9.6%. 122 The epidemic was over by July 2003, and human-to-human transmission of the SARS virus globally has not been reported since. 122 The etiologic agent of SARS is a novel human coronavirus (SARS-CoV) that is not closely related to other human or animal coronavi- ruses 122 (Fig. 77-12) . SARS-CoV exhibits 99.8% homology between SARS-like coronaviruses found in animal markets. 122, 123 Epidemiology SARS is a zoonotic disease that can be transmitted by droplet or contact routes. 122, 124, 125 The virus was transmitted from exotic animals to food handlers or workers in the food markets in Guangdong Province and other Asian countries. 122 The incubation period of SARS ranges from 2 to 14 days (mean 5 days). 122, 126 Maximal infectivity occurs in the second week of illness, at the time of rapid clinical deterioration, which correlates with the peak viral load. 126 It is important to emphasize that a single case of SARS could trigger a global pandemic. Vigilant surveillance and strict infection control measures among suspected cases and contacts are critical to minimize spread. 122 Presenting symptoms include chills, myalgias, malaise, and headache. 127, 128 Fever is present in greater than 95% of cases. 122, 127, 128 Rhinorrhea and sore throat are uncommon in SARS. 128 Diarrhea occurs in up to 70% of patients. 126, 127 Lymphopenia, thrombocytopenia, and elevations in creatine kinase (CK) and lactate dehydrogenase (LDH) are early fi ndings. 127, 128 During the fi rst few days of the illness, respiratory symptoms are absent and chest radiographs may be normal. By 7 to 10 days, respiratory symptoms develop or worsen. 126 Pulmonary infi ltrates, ground-glass opacities, and multifocal consolidation are usually evident on chest computed tomography scans. 126 Most patients recover spontaneously by the second or third week of illness. 122 However, 20% to 30% develop progressive respiratory failure requiring mechanical ventilation (similar to acute respiratory distress syndrome [ARDS]). 122, 129 The median time from disease onset to mechanical ventilation among patients who developed respiratory failure was 9 days (range 7 to 13 days). 122 Mortality in this subset is approximately 50%. 122 SARS is uncommon in children, and has a milder course. 122 Atypical presentations of SARS (e.g., fever and diarrhea without respiratory manifestations 130, 131 or lack of symptoms) may result in delayed diagnosis. Given the potential for pandemic spread of SARS, rapid diagnostic confi rmation is essential for suspected cases. SARS should be considered in patients with pneumonia and ARDS of unknown etiology and one of the following risk factors: travel to mainland China or Asia (within 10 days) or employment in occupations at high risk (e.g., exposure to wildlife or other animals that may be reservoirs; health care workers or laboratory workers with close contact to SARS-CoV). 122 Even a single case mandates immediate efforts to identify the source and potential contacts. 122 When a case of SARS is suspected, public health authorities should be contacted immediately and can guide appropriate diagnostic workup and infection control measures. Samples of nasopharyngeal aspirates, respiratory secretions, and stool should be sent for cultures and RT-PCR. 122 However, virus isolation using cell culture is relatively insensitive, requires several days, and must be performed in a laboratory with biosafety level III capability. 132 Detection of viral RNA by RT-PCR provides rapid results, with sensitivity rates greater than 80% at days 9 to 12 of the illness, but less than 50% at earlier or later time points. 122 Serologic detection of an antibody response to SARS-CoV is the gold standard. 122 Acute and convalescent (3 to 4 weeks) sera should be obtained. 122 Seroconversion occurs in 50% of patients by day 10 and greater than 90% by day 28. 122 Serologies are useful for epidemiologic investigations, but are less valuable in individual patients because of the time lag between infection and seroconversion. Personal protective equipment, handwashing, and infection control measures are essential when collecting, transporting, and handling specimens. 122 Because of the potential for rapid epidemic spread, patients with SARS should be admitted to the hospital, and rigorous infection control measures are essential. 122 Droplet and Contact Precautions are mandatory. 122 Hypoxemic patients require careful monitoring, and in severe cases, mechanical ventilation. 122 Procedures that involve airway manipulation (e.g., intubation, bronchoscopy, suctioning, nebulized therapy) should be performed only when essential, and under tightly controlled conditions. 122 No treatment has been shown to infl uence mortality or clinical outcomes in SARS. 122 Intravenous ribavirin was ineffective and had signifi cant toxicity. 133 Corticosteroids were used in uncontrolled studies, but were of unproven benefi t. 122 Other strategies employed include interferon alfa, lopinavir/ritonavir, and Chinese herbal medications 122 ; none is of proven effi cacy. Vaccines are not yet available in humans. 67 Hantavirus is an RNA virus that causes the hantavirus pulmonary syndrome (HPS) or hantavirus cardiopulmonary syndrome (HCPS) in the Americas 134-136 and hemorrhagic fever renal syndrome (HFRS) in Asia and Europe. 136 Hantavirus is a genus of RNA viruses in the Bunyaviridae family and is the only group in this family that is not a naturally arthropod-borne virus 136 (Fig. 77-13 ). More than 25 viruses have been identifi ed within the genus Hantavirus. 36 Hantaviruses are hosted in nature by rodents (the source of transmission to humans). 135, 136 Epidemiology Three distinct groups of hantaviruses have been recognized, and result in distinct clinical presentations. The Hantaan virus (HTN), fi rst isolated in Korea in 1978, is a cause of HFRS in Asia and Europe. 136 The second group of viruses, primarily found in the Americas, is associated with a severe pulmonary capillary leak syndrome and high mortality. 137 The fi rst cases of HPS, due to the Sin Nombre (SN) virus, were described in the Four Corners region of New Mexico in 1993. 137 In North America, the SN virus is by far the most common, but other types have been described (e.g., Bayou virus, Black Creek Canal virus, New York virus, Monongahela virus). 135 South America were described in 1997. 138 By 2002, HPS had been confi rmed in at least six countries in South America (Argentina, Bolivia, Brazil, Chile, Uruguay, and Paraguay). 135 The fi rst case of human hantavirus infection in Central America was described in Panama in February 2000. 135 Several types of hantavirus were described in those outbreaks. The Andes virus was the predominant species in Chile and Argentina, whereas other subtypes were identifi ed in other countries (e.g., Laguna Negra virus in Paraguay; Choclo virus in Panama; Juquitiba virus in Brazil). 135, 136 A third group of hantaviruses, associated with the subfamily Arvicolinae, has been detected in North America and Europe, and may result in less severe forms of HFRS. 139 In this chapter, we restrict our discussion to respiratory infections due to hantaviruses in North America (principally the SN virus). Hantaviral infections in North America remain exceedingly rare, with a seroprevalence of less than 0.1%. 136 Since the initial report of HCPS in New Mexico in 1993, fewer than 500 cases have been reported in North America. 136 Inhalation of aerosolized virus particles present in urine, feces, or saliva of rodents is the most important route of human infection. 136 Following excretion by rodents, hantaviruses may remain infectious for several days. 136 Outbreaks of hantavirus infections in humans are related to variations in rodent density (e.g., due to climate and food supply) and rodents invading peridomestic environments. 135, 136, 139 Person-to-person transmission has not been described in North America, Europe, or Asia, 136 but was described in several cases in Argentina and Chile. 138, 140 Incubation period ranges from 7 to 39 days. 136, 141 In the most severe cases, hantavirus elicits a pulmonary capillary leak syndrome, producing ARDS and cardiogenic shock. 136 Typically, HCPS is characterized by three phases: prodromal, cardiopulmonary, and recovery. 136 In the prodromal phase (1 to 5 days), nonspecifi c symptoms of fever, headache, malaise, and myalgia are present. 136 Gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea, abdominal pain) may be present. 136 Importantly, rhinorrhea or nasal congestion (often the presenting features of other respiratory viral syndromes) are absent in this early phase. 136 During the next (cardiopulmonary) phase, dyspnea, cough, and pulmonary infi ltrates develop. 136 Thrombocytopenia occurs in 80% to 95% of patients with HCPS, and is usually present even in the early (prodromal phase). 136 Other laboratory aberrations may include hypoalbuminemia and elevations in transaminases, creatinine, CK, and LDH. 136 With the onset of the cardiopulmonary phase, dyspnea, hypoxemia, hypotension, or cardiovascular collapse may develop. 136 During this phase, hematocrit and leukocyte counts rise. 136 Rapid progression to fulminant pulmonary and/or cardiac failure may occur over the next 8 to 24 hours, with mortality rates exceeding 30% to 50%. 136 Pulmonary hemorrhage is rare with SN virus, but may complicate severe HCPS due to Andes virus. 136 Pulmonary edema may refl ect capillary leak as well as severe myocardial depression. 136 As myocardial function worsens, pulmonary capillary wedge pressure rises and cardiac index is low and resistant to fl uid resuscitation. 136 In addition, arrhythmias and cardiogenic shock may develop. Interestingly, at least one third of patients with SN infection do well, with modest or no pulmonary edema. 136 No clinical or laboratory features during the prodromal or early cardiopulmonary phases predict the ultimate severity of the disease. 136 Further, serologic epidemiologic studies cited serum antibodies to hantavirus in up to 13% of local community residents with no clinical evidence for illness, 135 suggesting that mild or asymptomatic hantavirus infections occur in humans. A careful history is critical. Hantavirus exposure should be considered in individuals who reside in or visit rural locations, even if an overt history of rodent exposure is lacking. Laboratory criteria suggestive of HCPS include thrombocytopenia (<150 × 10 3 /μL), hemoconcentration (hematocrit >50% in men or >48% in women), lack of toxic granulations in neutrophils, left shift of myeloid series, and greater than 10% immunoblasts. 136 A defi nitive diagnosis is made by serologies; serum antibodies are usually present on the fi rst day of symptoms. 136 Viral antigen detection in fi xed tissue by immunohistochemistry is sensitive and specifi c. 136 Viral RNA can be detected from serum or tissues by RT-PCR. 136 No specifi c antiviral therapy for HCPS exists. 136 Treatment is supportive and directed toward treating shock and acute respiratory, cardiac, or renal failure. 136 Because HCPS is associated with severe myocardial depression, aggressive fl uid resuscitation is discouraged. 136 Early use of vasopressors should be initiated. Extracorporeal membrane oxygenation may be effi cacious in extreme, fulminant cases of HPS. 136 Hyperimmune serum from convalescent patients is promising. 136 High levels of neutralizing antibodies correlated with improved survival and persist for years in survivors. 136 ADENOVIRUS Adenoviruses typically cause mild, self-limited infections involving the URT, gastrointestinal tract, or conjunctivae. 142 Adenovirus infections are more common in children, owing to lack of humoral immunity. 16, 142 The disease is more severe and dissemination is more likely in immunocompromised hosts. 16, [142] [143] [144] Pneumonia develops in fewer than 1% of immunocompetent patients with AdV infections, 145, 146 but in up to 10% of immunocompromised patients. 16, 142 Fatality rates for severe AdV pneumonia range from 10% to 70%. 16, 142 Virology Human AdV is a family of double-stranded nonenveloped DNA viruses 147 (Fig. 77-14) . Fifty-one serotypes and six species (A through F) are recognized; one third of serotypes are associated with human disease. 147 Manifestations of AdV are related to specifi c species and strains. 142, 144 In immunocompetent children, species B and C predominate (>95%), typically AdV strains 1 to 7. 144, 148 Most infections among military recruits are due to AdV strains 4 and 7. 145, 146 Gastroenteritis is associated with enteric AdV strains 40 and 41, and hemorrhagic gastritis with AdV 11, 33, 34, and 35. 16 Among HSCT recipients, most infections are due to AdV species B and C, 142,149 but signifi cant diversity 144 and even multiple serotypes in individual patients 144, 150 have been noted. Adenovirus is a common pathogen among children and adults, and accounts for at least 5% to 10% of pediatric and 1% to 7% of adults RTIs. 142 Infections occur throughout the year, with no seasonal variation. 142 Transmission of AdV can occur via inhalation of aerosolized droplets, direct conjunctival inoculation, fecal-oral spread, or exposure to infected tissue or blood. 142 The incubation period ranges from 2 to 14 days, and depends upon viral serotype and mechanism of transmission. 142 Infection can be by reactivation or new acquisition from exogenous sources. 142, 144 Rates of AdV infection are higher among children (due to lack of immunity) and immunosuppressed patients. 16, 142, 151 The incidence of AdV infections is 5% to 22% among SOT recipients 142, 152, 153 and 3% to 47% among HSCT recipients. 16, [142] [143] [144] 148, 150, [153] [154] [155] Risk factors for AdV infections among HSCT recipients include pediatric age group, allogeneic HSCT, severe T-cell depletion, and graft-versus-host disease. 142, 143, [153] [154] [155] Severe lymphopenia is associated with disseminated and often fatal disease. 142 Among SOT recipients, risk factors include pediatric age group, receipt of antilymphocyte antibodies, and donorpositive/recipient-negative AdV status. 142 Epidemic AdV infections may spread rapidly in closed environments such as military recruit barracks, 145, 156 civilian job training facilities, long-term care facilities, 151 and psychiatric care facilities, 157 as well as among hospitalized or institutionalized civilians. 158 Adenovirus accounts for greater than 50% of febrile respiratory illnesses among healthy military recruits. 145, 146, 156 Surveillance of U.S. recruits in training from 1999 to 2004 cited greater than 73,000 AdV infections, with peak illness rates in weeks 3 to 5 of training. 156 Serotype 4 accounted for greater than 95% of infections. 156 Importantly, the annual rate of AdV infections rose more than threefold after vaccine usage ceased. 156 High baseline immunity against AdV (titer of >1:32) confers substantial protection. 146 Adenoviral infections typically cause self-limited respiratory, gastrointestinal, or conjunctival disease. 142 Less common manifestations of AdV infections include hepatitis, hemorrhagic cystitis, nephritis, encephalitis, pancreatitis, and disseminated disease. 159, 160 Respiratory symptoms range from mild coldlike symptoms to severe (sometimes lethal) pneumonia and ARDS. 142, 157 Pneumonia due to AdV is rare in immunocompetent adults, but life-threatening cases have been described. 146 Gastrointestinal symptoms range from mild diarrhea to hemorrhagic colitis. 142 Hepatitis is often associated with subgroup C viruses (types 1, 2, and 5), and hemorrhagic cystitis with AdV types 11, 34, and 35. 142 The presence of AdV in urine is usually associated with hemorrhagic cystitis. 142 Severe AdV infections are rare among immunocompetent hosts, but dissemination occurs in 10% to 30% of HSCT recipients. 16, [142] [143] [144] 150, 154, 155 Adenovirus infections in SOT recipients may lead to graft loss or death. 161 Among HSCT recipients with symptomatic AdV disease, fatality rates range from 19% to 65%. 16, 142, 143, 153, 154 Case fatality rates for untreated AdV pneumonia may exceed 50%. 16, 142 Diagnosis Viral cultures are diffi cult and may take up to 21 days to isolate AdV. 16, 142 The commercially available AdV EIA test for stool specimens detects only serotypes 40 and 41. 16 Adenovirus nuclear inclusions may be observed in tissue. 142 RT-PCT of AdV DNA in plasma or infected sites is the preferred technique 142 and is highly sensitive for disseminated disease. 160, 162 Persistently high titers correlate with clinical disease. 160 Serial RT-PCR assays of blood and stool weekly may detect AdV disease prior to the onset of symptoms, and facilitate early "preemptive" therapy. 144, 152, 154, 163 However, the role of routine surveillance is controversial. 142 No antiviral drug has been approved to treat adenovirus. Prospective randomized controlled trials are lacking. Cidofovir, a cytosine nucleotide analogue that inhibits DNA polymerase, has the greatest in vitro activity; most, but not all, species are resistant to ribavirin. 164, 165 Ganciclovir displays in vitro activity against AdV, but has no role to treat AdV infections. 142 While not all AdV infections require treatment, cidofovir (available only intravenously) is the preferred therapeutic agent. 142 Numerous studies of HSCT and SOT recipients have documented favorable responses to cidofovir. 143, 144, 154, 163, 166, 167 Major dosing regimens include intravenous cidofovir 5 mg/kg once weekly or 1 mg/ kg thrice weekly for 4 to 6 weeks. 163 Cidofovir is generally well tolerated, 154,163 but may cause nephrotoxicity. 142 Hydration and probenacid may minimize nephrotoxicity. 142, 154, 167, 168 Newer lipid formulations of cidofovir exhibit increased activity against AdV and are less toxic, but not yet available. 169 Reduction of immunosuppression 154 or immune reconstitution of HSCT recipients 143 may have adjunctive roles. IVIG has been used (together with cidofovir), but data are insuffi cient to assess effi cacy. 143 Not all patients with AdV infections require treatment. 142 Interestingly, in a cohort of SOT recipients, all 19 with AdV infection recovered spontaneously. 152 Similarly, in one study of pediatric HSCT recipients, AdV viremia was detected in 42% and cleared without therapy in 64%. 170 Oral vaccines against AdV types 4 and 7 were developed for the U.S. military, and routine vaccination began at U.S. recruit training camps in 1971. 156 These vaccines were safe and highly effi cacious, 145 but production ceased in 1996, and available stores were depleted by 1999. 156 Restoration of an effective AdV vaccine is anticipated in 2008. 156 The spread of infl uenza and other respiratory viruses: complexities and conjectures Infl uenza: evolving strategies in treatment and prevention Vaccines for seasonal and pandemic infl uenza Pandemic (avian) infl uenza Epidemiology of seasonal infl uenza: use of surveillance data and statistical models to estimate the burden of disease Role of the laboratory in diagnosis of infl uenza during seasonal epidemics and potential pandemics Incidence of adamantane resistance among infl uenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern Mortality associated with infl uenza and respiratory syncytial virus in the United States Lower clinical effectiveness of oseltamivir against infl uenza B contrasted with infl uenza A infection in children The underrecognized burden of infl uenza in young children Infl uenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy Preparing for the next pandemic Prevention and treatment of infl uenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents Estimating infl uenza hospitalizations among children Incidence of outpatient visits and hospitalizations related to infl uenza in infants and young children Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodefi ciency virus infection Recovery of drug-resistant infl uenza virus from immunocompromised patients: a case series Enhanced virulence of infl uenza A viruses with the haemagglutinin of the 1918 pandemic virus Infl uenza A and B virus infections in children Reye's syndrome and salicylate use Clinical features of infl uenza A virus infection in older hospitalized persons Prevention and treatment of infl uenza Neuraminidase inhibitors for infl uenza Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study Factors infl uencing the effectiveness of oseltamivir and amantadine for the treatment of infl uenza: a multicenter study from Japan of the 2002-2003 infl uenza season Adamantane resistance in infl uenza A Adamantane resistance among infl uenza A viruses isolated early during the 2005-2006 infl uenza season in the United States Detection of amantadine-resistant variants among avian infl uenza viruses isolated in North America and Asia Prevention and control of infl uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) Management of infl uenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis Antiviral management of seasonal and pandemic infl uenza Risk of pneumonia and other complications of infl uenza-like illness in patients treated with oseltamivir Detection and control of infl uenza outbreaks in well-vaccinated nursing home populations Use of oseltamivir during infl uenza outbreaks in Ontario nursing homes Effectiveness of neuraminidase inhibitors in treatment and prevention of infl uenza A and B: systematic review and meta-analyses of randomised controlled trials Oseltamivir-resistant infl uenza? Oseltamivir resistance-disabling our infl uenza defenses The run on Tamifl u-should physicians prescribe on demand? Neuraminidase inhibitor-resistant infl uenza viruses may differ substantially in fi tness and transmissibility Neuraminidase sequence analysis and susceptibilities of infl uenza virus clinical isolates to zanamivir and oseltamivir Resistant infl uenza A viruses in children treated with oseltamivir: descriptive study Avian infl uenza A (H5N1) infection in humans Oseltamivir resistance during treatment of infl uenza A (H5N1) infection Universal infl uenza vaccination in the United States: are we ready? Report of a meeting Effectiveness of infl uenza vaccine in the community-dwelling elderly Different approaches to infl uenza vaccination Prevention of antigenically drifted infl uenza by inactivated and live attenuated vaccines Prevention and control of infl uenza: recommendations of the Advisory Committee on Immunization Practices (ACIP) Effi cacy and effectiveness of infl uenza vaccines in elderly people: a systematic review Clinical effectiveness of infl uenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study Infl uenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP) Vaccinating healthcare workers against infl uenza to protect the vulnerable-is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation Assessment of the effi cacy and effectiveness of infl uenza vaccines in healthy children: systematic review Infl uenza vaccine in healthy children: a metaanalysis Herd immunity in adults against infl uenzarelated illnesses with use of the trivalent-live attenuated infl uenza vaccine (CAIV-T) in children Effectiveness of school-based infl uenza vaccination Outbreak of avian infl uenza A (H5N1) virus infection in Hong Kong in 1997 Human and avian infl uenza viruses target different cell types in cultures of human airway epithelium Epidemiology of WHO-confi rmed human cases of avian infl uenza A (H5N1) infection Characterization of avian H5N1 infl uenza viruses from poultry in Hong Kong Re-emergence of fatal human infl uenza A subtype H5N1 disease Transmission of H7N7 avian infl uenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands Human illness from avian infl uenza H7N3, British Columbia Human infection with an avian H9N2 infl uenza A virus in Hong Kong in 2003 Probable person-to-person transmission of avian infl uenza A (H5N1) Distribution of amantadine-resistant H5N1 avian infl uenza variants in Asia Progress in respiratory virus vaccine development Respiratory syncytial virus infection in adults Respiratory syncytial virus and parainfl uenza virus Respiratory syncytial virus infections in previously healthy working adults Respiratory syncytial virus infection in elderly and high-risk adults Respiratory viral infections in patients with chronic, obstructive pulmonary disease Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease Infl uenza-and RSV-associated hospitalizations among adults Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? The similarities and differences of epidemic cycles of chronic obstructive pulmonary disease and asthma exacerbations Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease Respiratory syncytial virus, airway infl ammation, and FEV1 decline in patients with chronic obstructive pulmonary disease Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation-a compassionate use experience Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation Epidemiology and clinical impact of parainfl uenza virus infections in otherwise healthy infants and young children <5 years old Prolonged outbreak of human parainfl uenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis Acute respiratory tract infection in daycare centers for older persons Parainfl uenza type 3 infection post stem cell transplant: high prevalence but low mortality Parainfl uenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome Airfl ow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses Treatment of parainfl uenza virus 3 pneumonia in a cardiac transplant recipient with intravenous ribavirin and methylprednisolone A newly discovered human pneumovirus isolated from young children with respiratory tract disease Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults Genetic variability of human metapneumovirus infection: evidence of a shift in viral genotype without a change in illness Human metapneumovirus An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility Detection of severe human metapneumovirus infection by real-time polymerase chain reaction and histopathological assessment Differences in clinical severity between genotype A and genotype B human metapneumovirus infection in children Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients Human metapneumovirus infections in young and elderly adults Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease A summer outbreak of human metapneumovirus infection in a long-term-care facility Human metapneumovirus infections in hospitalized children Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis Human metapneumovirus and exacerbations of chronic obstructive pulmonary disease Effect of ribavirin and glucocorticoid treatment in a mouse model of human metapneumovirus infection Comparison of the inhibition of human metapneumovirus and respiratory syncytial virus by ribavirin and immune serum globulin in vitro Rhinovirus and coronavirus infections The common cold: a review of the literature Rhinovirus and the lower respiratory tract Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia Role of viruses in exacerbations of chronic obstructive pulmonary disease Acute otitis media and respiratory viruses Human rhinoviruses in otitis media with effusion Detection of rhinoviruses by tissue culture and two independent amplifi cation techniques, nucleic acid sequence-based amplifi cation and reverse transcription-PCR, in children with acute respiratory infections during a winter season Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China Severe acute respiratory syndrome (SARS) coronavirus Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms Bats are natural reservoirs of SARS-like coronaviruses The severe acute respiratory syndrome Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study Early diagnosis of SARS: lessons from the Toronto SARS outbreak Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients Mild illness associated with severe acute respiratory syndrome coronavirus infection: lessons from a prospective seroepidemiologic study of health-care workers in a teaching hospital in Singapore Severe acute respiratory syndrome Detection of SARS coronavirus in patients with suspected SARS Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers Diagnosis and treatment of New World hantavirus infections Outbreak of hantavirus pulmonary syndrome Hantavirus cardiopulmonary syndrome Genetic identifi cation of a hantavirus associated with an outbreak of acute respiratory illness An outbreak of hantavirus pulmonary syndrome Newly recognized hantaviruses associated with hantavirus pulmonary syndrome in northern Brazil: partial genetic characterization of viruses and serologic implication of likely reservoirs Person-to-person transmission of Andes virus Incubation period of hantavirus cardiopulmonary syndrome Adenovirus infections in transplant recipients Treatment of adenovirus disease in stem cell transplant recipients with cidofovir Identifi cation of adenoviruses from high risk pediatric stem cell transplant recipients and controls Epidemic of adenovirus-induced respiratory illness among US military recruits: epidemiologic and immunologic risk factors in healthy, young adults Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies Molecular typing of human adenoviruses by PCR and sequencing of a partial region of the hexon gene Typing of human adenoviruses in specimens from immunosuppressed patients by PCR-fragment length analysis and real-time quantitative PCR Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management Sequential emergence of multiple adenovirus serotypes after pediatric stem cell transplantation Outbreak of human adenovirus type 3 infection in a pediatric long-term care facility-Illinois A surveillance study of adenovirus infection in adult solid organ transplant recipients Adenoviral infections in pediatric transplant recipients: a hospital-based study Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome Vaccine-preventable adenoviral respiratory illness in US military recruits Multiple cases of life-threatening adenovirus pneumonia in a mental health care center Nosocomial adenovirus infection: molecular epidemiology of an outbreak Pancreatitis and adenoviral infection in children after blood and marrow transplantation Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease Adenovirus infection in the lung results in graft failure after lung transplantation Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients Antiadenovirus activities of several classes of nucleoside and nucleotide analogues In vitro susceptibility of adenovirus to antiviral drugs is species-dependent Disseminated adenovirus infection with respiratory failure in pediatric liver transplant recipients: impact of intravenous cidofovir and inhaled nitric oxide Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients Adenovirus-associated hemorrhagic cystitis in a pediatric renal transplant recipient Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary?